# A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery

> **NCT06529432** · PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 96 (estimated)

## Conditions studied

- Local Analgesia Via Nerve Block

## Interventions

- **DRUG:** Bupivacaine Liposome Injection
- **DRUG:** Bupivacaine Hydrochloride Injection

## Key facts

- **NCT ID:** NCT06529432
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-03
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06529432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06529432, "A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06529432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*